Bromodomain Protein Inhibition Protects β-Cells from Cytokine-Induced Death and Dysfunction via Antagonism of NF-κB...

Area of Science:

• Immunology
• Endocrinology
• Molecular Biology

Background:

• Cytokine-induced beta-cell apoptosis is a key factor in type 1 diabetes (T1D) pathogenesis.
• BET (bromo- and extra-terminal) proteins are epigenetic regulators of immune responses, with preclinical studies suggesting BET inhibitors may protect against T1D.
• The specific impact of BET protein inhibition on beta-cell function under cytokine stimulation remains unexplored.

Purpose of the Study:

• To investigate the protective effects of the BET protein inhibitor I-BET on beta-cells against cytokine-induced dysfunction and apoptosis.
• To explore the underlying molecular mechanisms of I-BET's action in a type 1 diabetes context.

Main Methods:

• Utilized in vitro cell culture and in vivo mouse models (NOD mice and STZ-induced T1D model).
• Assessed beta-cell apoptosis, dysfunction, and survival following cytokine exposure and I-BET treatment.
• Performed RNA-sequencing (RNA-Seq) to analyze gene expression changes and signaling pathways, including NF-kB and FOXO1.

Main Results:

• I-BET treatment protected beta-cells from cytokine-induced dysfunction and apoptosis in vitro.
• In vivo administration of I-BET reduced beta-cell apoptosis in a mouse model of T1D.
• Mechanistically, I-BET inhibited NF-kB signaling and enhanced FOXO1-mediated antioxidant responses, while suppressing apoptosis pathways and maintaining key beta-cell genes like Pdx1 and Ins1.

Conclusions:

• I-BET demonstrates significant cytoprotective effects on beta-cells against cytokine-induced damage.
• Targeting BET proteins with inhibitors like I-BET shows therapeutic potential for preserving beta-cell mass and function in type 1 diabetes.